How Amgen, In A Buy Zone, Is Taking On Novartis With A First-Ever
How Amgen, In A Buy Zone, Is Taking On Novartis With A First-Ever Investor's Business Daily
Covered in this story
Analyst targets on Amgen
- Freedom Broker: at $460 · target $470 by Nov 2027 · Hold via Investing.com
- Oppenheimer: at $439 · target $480 by Oct 2027 · Outperform via Investing.com India
- Cantor Fitzgerald: at $432 · target $440 by Oct 2027 · neutral via MarketBeat
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 30 Mar 2026.
Summary aggregated from Investor's Business Daily's public RSS feed. The full reporting belongs to Investor's Business Daily — please read it on their site.